Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
41,109,611
-
Share change
-
+603,430
-
Total reported value
-
$342,872,903
-
Put/Call ratio
-
0%
-
Price per share
-
$8.35
-
Number of holders
-
121
-
Value change
-
+$7,903,036
-
Number of buys
-
52
-
Number of sells
-
48
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q4 2021
As of 31 Dec 2021,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
121 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,109,611 shares.
The largest 10 holders included
Deep Track Capital, LP, PFM Health Sciences, LP, RTW INVESTMENTS, LP, ORBIMED ADVISORS LLC, TRV GP II, LLC, BlackRock Inc., CITADEL ADVISORS LLC, VANGUARD GROUP INC, Sofinnova Investments, Inc., and Woodline Partners LP.
This page lists
121
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.